XML 128 R61.htm IDEA: XBRL DOCUMENT v3.25.2
Segment Information - Schedule of Financial Information (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended
Jan. 31, 2025
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Operating Expenses:          
Research and development   $ 2,253 $ 2,601 $ 4,856 $ 5,842
Operating loss   (4,868) (5,523) (10,716) (12,124)
Other income, net   (7) (14) (111) (201)
Benefit from income taxes $ 962 0 0 (962) (798)
Net loss   (4,659) (5,044) (9,383) (10,445)
Revenue   70 0 70 0
Reportable Segment          
Operating Expenses:          
Research and development   2,253 2,601 4,856 5,842
General and administrative   2,685 2,922 5,930 6,282
Investor relations/public relations/communications   309 347 640 632
Finance   538 585 1,167 1,165
Legal   327 239 551 909
Business development   140 145 267 317
Share based compensation expense   212 200 616 568
Other   2 134 387 287
Operating loss   (4,868) (5,523) (10,716) (12,124)
Other income, net   209 479 371 881
Benefit from income taxes   0 0 (962) (798)
Net loss   (4,659) (5,044) (9,383) (10,445)
Cash and marketable securities   21,970 38,262 21,970 38,262
Reportable Segment | Segment Reporting, Reconciling Item, Corporate Nonsegment          
Operating Expenses:          
General and administrative   1,157 1,272 2,302 2,404
Reportable Segment | BOLSTER trial          
Operating Expenses:          
Research and development   605 1,075 1,393 2,345
Reportable Segment | ASCEND trial          
Operating Expenses:          
Research and development   32 94 53 138
Reportable Segment | Chemistry, manufacturing and controls          
Operating Expenses:          
Research and development   167 284 387 939
Reportable Segment | Clinical department          
Operating Expenses:          
Research and development   991 1,056 2,148 2,190
Reportable Segment | Other          
Operating Expenses:          
Research and development   $ 458 $ 92 $ 875 $ 230